• FDA granted Premarket Approval for Implantica’s RefluxStop implant for GERD, clearing the product for U.S. commercialization.
• Approval was backed by FDA review of long-term clinical data supporting 5-year safety and effectiveness.
• U.S. rollout set to start at selected specialist centers, with uptake expected to build as surgeons are trained.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Implantica AG published the original content used to generate this news brief via PR Newswire (Ref. ID: HS31036) on August 21, 2026, and is solely responsible for the information contained therein.